What if a rare and deadly form of lung cancer, long considered a near-hopeless battle, suddenly had a new weapon in its fight? Picture a patient, grappling with the weight of a diagnosis of HER2-mutant non-small cell lung cancer (NSCLC), now finding a glimmer of possibility with an oral therapy
In the fast-evolving world of biopharma manufacturing, where innovation meets urgent medical needs, BICO Group AB stands as a pivotal player with a sharp focus on lab automation and supply chain solutions. The biopharma sector, particularly the realm of cell and gene therapies (CGTs), is on a
Imagine a political landscape where access to health care hinges on the drawing of district lines, a scenario unfolding right now as advocacy groups and lawmakers clash over congressional maps in a heated battle for influence. With reproductive rights and health funding under threat from
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent European Commission approval of Cabometyx for advanced
Imagine a diagnosis so devastating that it offers a median survival of just one year, primarily striking children and young adults with little hope for effective intervention. Diffuse midline glioma with an ### K27M mutation, an ultra-rare and aggressive brain cancer, affects roughly 2,000
What happens when a relentless cancer, deemed incurable, meets a groundbreaking therapy that defies the odds? For the 15,000 Americans diagnosed annually with follicular lymphoma—a slow-growing but persistent form of non-Hodgkin lymphoma—this question is no longer hypothetical. A stunning phase 3
